OrthoPediatrics Corp. is a global medical device company headquartered in Warsaw, Indiana, specializing in pediatric orthopedic care. The company designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces tailored to the needs of pediatric surgeons, orthotists, and their patients. Its offerings include trauma and deformity correction devices, scoliosis treatment systems, sports medicine products, and clinical services aimed at improving the lives of children with orthopedic conditions.
- Trauma and Deformity - Provides implants and instruments for correcting pediatric trauma and deformities, including systems like PediLoc®, Cannulated Screws, and the Fassier-Duval Telescopic Intramedullary System®.
- Scoliosis - Offers innovative solutions for scoliosis treatment, including minimally invasive systems like RESPONSETM Spine and BandLoc™.
- Sports Medicine/Other - Delivers products for pediatric sports medicine and other orthopedic needs, such as ACL Reconstruction Systems and specialized bracing options.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David R. Bailey ExecutiveBoard | President and Chief Executive Officer | David R. Bailey has served as the President and Chief Executive Officer at KIDS since June 1, 2021. He joined the company in 2007 and was appointed as a board member on November 3, 2021. | View Report → | |
Fred L. Hite ExecutiveBoard | Chief Financial Officer | Fred L. Hite has served as CFO of OrthoPediatrics Corp. since February 2015 and concurrently as COO since June 2020. He has also been a Director since August 2015 and previously served as CFO and Investor Relations Officer at Symmetry Medical Inc. from 2004 to 2014. | ||
Daniel J. Gerritzen Executive | Executive Vice President (Legal), General Counsel, and Secretary | Daniel J. Gerritzen has served as General Counsel since 2009, Secretary since 2013, and became Executive Vice President in 2022 at KIDS, demonstrating his extensive legal and executive leadership. Previously, he was a partner and continues to serve as Of Counsel at Dentons Bingham Greenebaum LLP. | ||
Gregory A. Odle Executive | President of Scoliosis | Gregory A. Odle is the President of Scoliosis at OrthoPediatrics Corp since 2022. He previously served as Executive Vice President from 2011 to 2022 and was a Board of Directors member from 2007 to 2013. | ||
Joseph W. Hauser Executive | President of Trauma, Deformity, and OPSB | Joseph W. Hauser is the President of Trauma, Deformity, and OPSB at OrthoPediatrics since 2024. Previously, he served as President of Trauma and Deformity Correction from 2022 to 2024 and as Senior Vice President from 2021 to 2022. | ||
Bryan W. Hughes Board | director | Managing Director and Group Head of Medical Technology Investment Banking at P&M Corporate Finance, LLC | Bryan W. Hughes has served as a director at OrthoPediatrics Corp (KIDS) since 2012. He is also the Managing Director and Group Head of Medical Technology Investment Banking at P&M Corporate Finance, LLC since 2008. | |
David R. Pelizzon Board | Director | President of Squadron Capital LLC; Director at Alphatec Holdings, Inc. | David R. Pelizzon has served as Director at KIDS since 2011, playing a key role in the company’s board governance. He also brings extensive leadership experience from his roles as President of Squadron Capital LLC since 2008 and Director at Alphatec Holdings, Inc. since June 2020. | |
Mark C. Throdahl Board | Chairman of the Board | Chairman of OrthoPediatrics Corp. since 2024 , previously served as CEO from January 2011 to June 2021. | ||
Terry D. Schlotterback Board | Lead Independent Director | Chairman of the Board, Nextremity Products Inc. ; Board Member, OrthoLazer Inc. ; Advisor for Ignite Orthopedics Inc. | Terry D. Schlotterback has been a director at KIDS since 2009, currently serving as Lead Independent Director since June 2021 and previously as Chairman of the Board from September 2013 to June 2021. |
- Given the international revenue growth was only 5% in Q4 2024 due to deliberate shipment holds in South America to manage receivables affected by currency fluctuations, how do you plan to mitigate these currency risks and stimulate international growth moving forward?
- With gross profit margin decreasing to 68% in Q4 2024 from 71% in the prior year due to reclassification of certain expenses into cost of goods sold, what specific actions are you taking to improve gross margins, and is there potential for upside as you scale manufacturing and launch new products?
- Considering the $3.7 million restructuring charge associated with closing your Israel office and consolidating ApiFix production into the U.S., what impact will this have on your supply chain and production timelines, and are there risks related to this consolidation?
- You mentioned reducing set deployments to $15 million in 2025 compared to previous years; is there a risk that this lower level of investment might constrain growth in your Trauma and Deformity business in the future, potentially necessitating a larger deployment in subsequent years?
- With products like DF2 experiencing demand that exceeds expectations and current manufacturing capacity, how are you addressing supply constraints and what steps are you taking to scale manufacturing to meet both domestic and international demand without compromising quality?
Research analysts who have asked questions during ORTHOPEDIATRICS earnings calls.
Matthew O'Brien
Piper Sandler & Co.
4 questions for KIDS
Ryan Zimmerman
BTIG
3 questions for KIDS
Frederick Wise
Stifel
2 questions for KIDS
Joseph Conway
Needham & Company, LLC
2 questions for KIDS
Mike Matson
Needham & Company, LLC
2 questions for KIDS
Ben Haynor
Lake Street Capital Markets
1 question for KIDS
Benjamin Haynor
Lake Street Capital Markets
1 question for KIDS
Richard Newitter
Truist Securities
1 question for KIDS
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The company operates in the competitive orthopedic industry, which is subject to rapid technological changes and influenced by new product introductions. It is noted as a competitor in all three product categories, and the company's ability to compete depends on developing proprietary products that are cost-effective, safe, and effective, while also maintaining a dedicated selling organization viewed as a consultative resource by pediatric orthopedic surgeons. | |
The company is identified as a competitor in the orthopedic industry, which is characterized by intense competition and rapid changes. Competitors may develop new devices or treatment alternatives that could render the company's products obsolete or uncompetitive. Many competitors have substantially greater sales and financial resources, entrenched relationships with orthopedic surgeons, and more experience in launching and marketing products. | |
The company faces competition from this entity in the orthopedic industry, which is highly sensitive to the introduction of new products. Competitors may gain market advantages by developing and patenting competitive products earlier or obtaining regulatory clearances more rapidly. The frequent introduction of competing products may create market confusion, making it difficult to differentiate the benefits of the company's products. | |
This competitor is mentioned as operating in the orthopedic industry, which is intensely competitive and subject to rapid changes. The company notes that competitors may specialize in specific products or focus on particular market sectors, making it challenging to increase its overall market position. | |
Hanger clinics | The company identifies this entity as a competitor in the orthopedic industry, emphasizing the need to develop proprietary products that are cost-effective, safe, and effective to compete successfully. Competitors may employ pricing strategies that could adversely affect the pricing of the company's products. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Orthotic and Prosthetic Device Clinics in Virginia and Maryland | 2024 | Boston Orthotics & Prosthetics acquired these clinics on July 1, 2024 for a total consideration of $950,000—split evenly between a cash payment of $475,000 and a promissory note payable in six quarterly installments at 5.0% per annum—acquiring associated clinic inventory. |
Boston Orthotics & Prosthetics | 2024 | OrthoPediatrics Corp. completed its acquisition of Boston O&P on January 5, 2024 for $22 million in cash, with additional restricted stock awards totaling approximately 83,000 shares (valued at $2.5 million), thereby expanding its specialty bracing division and product portfolio and resulting in recognized goodwill and intangible assets, supported by an $80 million debt financing agreement. |
Medtech Concepts LLC | 2023 | OrthoPediatrics Corp. acquired Medtech Concepts LLC on May 1, 2023 for about $15.274 million, structured with an upfront cash payment, issuance of unregistered shares, and future annual payments; the acquisition provided an early-stage enabling technology platform that combines hardware, software, and data analytics aimed at enhancing perioperative efficiency. |
Rhino Pediatric Orthopedic Designs, Inc. | 2023 | Completed on July 1, 2023, the acquisition of Rhino Pediatric Orthopedic Designs, Inc. for $1,024,000 (comprising $546,000 in cash and a stock issuance of 11,133 shares) secured key assets including pediatric orthopedic products such as the Cruiser™, Kicker™, and Rhino Stomper™. |
MD Orthopaedics, Inc. | 2022 | OrthoPediatrics Corp. acquired MD Orthopaedics, Inc. on April 1, 2022 for approximately $18.5 million—through a mix of cash, unregistered stock (173,241 shares), and $2.5 million in restricted stock awards—to expand into non-operative pediatric treatments with its patented clubfoot products and boost a total addressable market by an estimated $600 million. |
Pega Medical Inc. | 2022 | On July 1, 2022, Pega Medical Inc. was acquired for a purchase price of about $32.045 million, primarily in cash (with approximately $1.052 million held in escrow) along with additional stock issuance and restricted stock units; the deal, supported by an increased revolving credit facility, enhanced OrthoPediatrics’ portfolio with trauma and deformity correction devices and widened its global market reach. |
Recent press releases and 8-K filings for KIDS.
- OrthoPediatrics Corp. is the only company focused exclusively on pediatric orthopedics, having helped over 1,200,000 children with its devices. The global market is estimated at $6.2 billion, with a U.S. addressable market of $2.6 billion.
- The company has achieved nearly 20% year-over-year growth for almost two decades. For 2025, OrthoPediatrics projects revenue between $237 million and $242 million and adjusted EBITDA between $15 million and $17 million.
- OrthoPediatrics anticipates achieving free cash flow breakeven in Q4 2025 and for the full year 2026.
- Key growth catalysts include the upcoming launch of the Vertiglyde system and the development of ELE, an electromechanical growing technology with breakthrough device designation, aiming for FDA approval and first surgeries next year.
- The company is also expanding its specialty bracing business (OPSB), having grown from 26 to over 40 clinics since the acquisition of Boston OMP, with plans to expand into 26 of 80 territories within the next three years.
- OrthoPediatrics Corp reported Q2 2025 revenue of $61.1 million, a 16% growth year-over-year, alongside a net loss of ($7.1 million) and diluted EPS of ($0.30). The company's Adjusted EBITDA for the quarter was $4.1 million.
- The company provided full-year 2025 revenue guidance of $237.0 million to $242.0 million, representing 16% to 18% growth, and Adjusted EBITDA guidance of $15.0 million to $17.0 million.
- Key strategic developments include the FDA approval of VerteGlide™ in April 2025 and the acquisition of Boston Orthotics & Prosthetics on January 5, 2024, for $22 million cash, expanding its specialty bracing division.
- OrthoPediatrics Corp. achieved record high total revenue of $61.1 million for the second quarter of 2025, an increase of 16% compared to the second quarter of 2024.
- Adjusted EBITDA for Q2 2025 increased by 58% to $4.1 million.
- The company reported a GAAP diluted loss per share of ($0.30) and an improved non-GAAP diluted loss per share of ($0.11) for the second quarter of 2025.
- OrthoPediatrics increased its full-year 2025 revenue guidance to a range of $237.0 million to $242.0 million, representing 16% to 18% growth over 2024 revenue.
- OrthoPediatrics Corp. (KIDS) announced the expansion of its OrthoPediatrics Specialty Bracing (OPSB) division with multiple new clinics and entry into two new territories.
- The expansion includes rapid growth of greenfield clinic locations in California (Los Angeles), Ohio (Dayton), and Colorado (Denver).
- OPSB also expanded through Acquihire opportunities, adding new operations in New York (greater NYC) and Ireland, which represents OPSB's first international market.
- This continued expansion is slightly ahead of the planned entry into four new target markets in 2025, aiming to provide access to millions of potential pediatric and adolescent patients.
- OrthoPediatrics Corp. (KIDS) announced on August 5, 2025, the continued expansion of its OrthoPediatrics Specialty Bracing (OPSB) division with multiple new clinics and entry into two new territories.
- The expansion includes new greenfield clinic locations in California (Los Angeles), Ohio (Dayton, within Dayton Children's Hospital), and Colorado (Denver).
- OPSB also expanded through "Acquihire" opportunities, adding new operations in New York (multiple patient locations within major Children's Hospital centers) and Ireland, marking Ireland as OPSB's first international market.
- Joe Hauser, OrthoPediatrics Specialty Bracing division President, stated that the company is slightly ahead of its planned entry into 4 new target markets in 2025.
- Revenue Growth: Q1 2025 revenue reached $52.4 million with a 17% year-over-year increase (domestic up 19% and international up 11%) .
- Improved Profitability: Adjusted EBITDA improved to ($0.4) million vs. ($1.1) million last year, with free cash flow usage reduced by 36% and expectations for positive free cash flow in Q4 2025 .
- Full-Year Guidance: Revenue guidance raised to $236–$242 million for 2025, reflecting anticipated 15–18% growth over 2024 .
- Product Milestones: Multiple FDA approvals secured for key products including the VerteGlide™ System (marking the company’s 80th product), sterile PNP Femur, sterile PNP Tibia, and the 3P Pediatric Plating Platform Hip System .
- Strategic Expansion: Continued OPSB clinic growth into new territories such as North Carolina, Florida, and Colorado, complemented by an extensive network of top children’s hospitals and targeted U.S. and international sales strategies .
- Innovation & Clinical Education: The May 7, 2025 presentation highlighted a focused strategy on pediatric orthopedics with an innovative product portfolio and dedicated clinical education initiatives .
- Forward-Looking Insights: Included key non-GAAP metrics and forward-looking statements to provide further insight into operating performance and future outlook .
- The presentation, filed as an 8-K, outlines OrthoPediatrics Corp’s commitment to pediatric orthopedics by showcasing a broad, innovative product portfolio and detailed strategic initiatives aimed at expanding market reach and clinical education.
- It also highlights forward-looking statements, recent M&A activities, and planned investments in new product launches to drive revenue acceleration and long-term growth.
- Q4 revenue of $52.7 million achieved a 40% YoY increase, with US revenue at $42.9 million (79% of total) .
- Updated 2025 guidance projects revenue of $235–242 million, adjusted EBITDA of $15–17 million, and anticipates the first quarter of positive free cash flow in Q4 2025 .
- Record pediatric care performance with over 34,000 children helped in Q4 and a full‐year milestone of more than 138,000 kids aided in its 18-year history .
- Adjusted EBITDA improved to $3.0 million in Q4 (up from $1.3 million) and reached $8.5 million over the full year .
- Strategic initiatives include scaling the OPSB business and executing cost efficiencies, highlighted by a $3.7 million restructuring charge for consolidating manufacturing from its Israel office to the US and Warsaw .
- Record Full Year 2024 Revenue: Achieved an all-time high of $205 million with a 38% year-over-year increase.
- 2025 Guidance: Projects revenue between $235 million to $242 million and an expected adjusted EBITDA of $15 million to $17 million.
- 8-K Investor Presentation Filed on January 14, 2025: Outlines a focused strategy on pediatric orthopedics.
- Strategic Growth Initiatives: Highlights an expanded, innovative product portfolio along with enhanced clinical education to capture a significant share of an underpenetrated global market.
- Forward-Looking Revenue & Investment Initiatives: Details upcoming product launches, strategic investments, and initiatives to broaden the surgeon network to accelerate market momentum.